| Vivelle-Dot Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Vivelle-Dot 0.1 mg/24 hours twice weekly | film, extended release | transdermal | 24.0 hour(s) | OTC |
| Vivelle-Dot 0.025 mg/24 hours twice weekly | film, extended release | transdermal | 24.0 hour(s) | OTC |
| Vivelle-Dot 0.0375 mg/24 hours twice weekly | film, extended release | transdermal | 24.0 hour(s) | OTC |
| Vivelle-Dot 0.05 mg/24 hours twice weekly | film, extended release | transdermal | 24.0 hour(s) | OTC |
| Vivelle-Dot 0.075 mg/24 hours twice weekly | film, extended release | transdermal | 24.0 hour(s) | OTC |
Posted by linc5723 about 1 year ago
Started using Vivelle-Dot 0.05 in March 2008 and in June of 2008 started getting an allergic reaction which was skin redness ...
Posted by alicew96 about 1 year ago
After approximately six months of Vivelle-Dot - .05 mg experienced increasingly severe back, calf, ankle and foot pain to th...
Posted by rrmatthai about 1 year ago
sever back and neck pain
Noven to Present at Raymond James Institutional Investors Conference - Business Wire (press release)
Noven’s leading transdermal products utilize its proprietary DOT Matrix ® drug delivery technology and include Vivelle-Dot ® (estradiol transdermal system), ...
Fri Feb 29 08:47:08 -0500 2008
Noven Receives FDA Warning Letter Related to Mid-2007 Facility ... - Genetic Engineering News (press release)
Its commercialized transdermal products include Vivelle-Dot(R) (estradiol transdermal system), the most prescribed estrogen patch in the US, ...
Thu Jan 10 10:47:32 -0500 2008
Noven's chief executive retires - Trading Markets (press release)
... Novogyne Pharmaceuticals, which has become a market leader in patches for post-menopausal female hormone treatments, such as the Vivelle-Dot patch. ...
Fri Jan 04 05:14:34 -0500 2008
estradiol - The most potent form of the naturally occurring steroid sex hormone in humans, produced by ovary, placenta, testis, and in small amount by adrenal cortex. Estradiol binds to a specific intracellular estrogen receptor located in female organs, breasts, hypothalamus and pituitary. The receptor-ligand complex promotes gene expression necessary for the maintenance of fertility and secondary sexual characteristics in females. In addition, estradiol exhibits mild anabolic and metabolic properties, and increases blood coagulability. Estradiol, the principal intracellular human estrogen, is substantially more active at the cellular level than its metabolites, estrone and estriol.